Results 71 to 80 of about 209,011 (190)

Longitudinal Trends in HIV-1 Subtypes and Drug Resistance in Children from Argentina over a 15-Year Period (2006-2021)

Revista de Investigación Clínica
Background: Human immunodeficiency virus (HIV) drug resistance is a major cause of treatment failure in children and adolescents infected with the virus.
Natalia J. López, Solange Arazi-Caillaud, Rosa M. Bologna, Andrea M. Mangano, Cristina P. Aulicino   +4 more
doaj   +1 more source

Molecular screening of antimalarial, antiviral, anti-inflammatory and HIV protease inhibitors against spike glycoprotein of coronavirus. [PDF]

J Mol Graph Model, 2021
Prashantha CN, Gouthami K, Lavanya L, Bhavanam S, Jakhar A, Shakthiraju RG, Suraj V, Sahana KV, Sujana HS, Guruprasad NM, Ramachandra R.   +10 more
europepmc   +1 more source

Repositioning HIV protease inhibitors and nucleos(t)ide RNA polymerase inhibitors for the treatment of SARS-CoV-2 infection and COVID-19. [PDF]

Eur J Clin Pharmacol, 2021
von Hentig N.
europepmc   +1 more source

Hyperlipidaemia - a risk factor for femoral head osteonecrosis (Legg-Calvè-Perthes-Like disease) in children with AIDS: case report

Brazilian Journal of Infectious Diseases
Although treatment of children infected with HIV with protease inhibitors has improved the survival of these patients, various adverse side effects have been reported, including metabolic abnormalities, such as hyperlipidaemia.
Paula Aguiar de Aragão, Renata B. P. Lemos, Maria Zilda Aquino, Heloísa Helena Souza Marques   +3 more
doaj   +1 more source

Cobicistat Boosts the Intestinal Absorption of Transport Substrates, Including HIV Protease Inhibitors and GS-7340, In Vitro

Antimicrobial Agents and Chemotherapy, 2012
E. Lepist, Truc K. Phan, A. Roy, Leah Tong, K. MacLennan, B. Murray, A. Ray   +6 more
semanticscholar   +1 more source

Treatment Outcome and Regimens of Lipid-Lowering Drugs among HIV-Infected Patients Receiving Protease Inhibitors

Journal of Health Science and Medical Research (JHSMR), 2016
Objective: To determine treatment outcome and regimens among human immunodeficiency virus (HIV)-infected patients receiving protease inhibitors treated with lipid-lowering drugs.
Krisda Boonthos, Weerawatwat Manosuthi, Thitima Pengsuparp, Chankit Puttilerpong   +3 more
doaj  

Interaction of HIV protease inhibitors with OATP1B1, 1B3, and 2B1

Xenobiotica; the fate of foreign compounds in biological systems, 2010
P. Annaert, Zhiwei Ye, Bruno Stieger, P. Augustijns   +3 more
semanticscholar   +1 more source

Clinical use of cobicistat as a pharmacoenhancer of human immunodeficiency virus therapy

HIV/AIDS: Research and Palliative Care, 2015
Nils von Hentig HIV Center, Medical Department II, Hospital of the JW Goethe-University, Frankfurt, BAG Darab-Kaboly/von Hentig, General Medicine and HIV Care, Frankfurt am Main, Germany Abstract: The pharmacoenhancement of plasma concentrations of ...
von Hentig N
doaj  

Complex Drug Interactions of HIV Protease Inhibitors 1: Inactivation, Induction, and Inhibition of Cytochrome P450 3A by Ritonavir or Nelfinavir

Drug Metabolism And Disposition, 2011
B. Kirby, A. Collier, E. Kharasch, D. Whittington, K. Thummel, J. Unadkat   +5 more
semanticscholar   +1 more source

Advancements in development of novel class of HIV protease inhibitors. [PDF]

Ann Med
Gu WG, Yin GZ, Zhang YP.
europepmc   +1 more source